Celltrion's latest marketcap:
As of 07/05/2025, Celltrion's market capitalization has reached $28.62 B. According to our data, Celltrion is the 762th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 28.62 B |
| Revenue (ttm) | 2.67 B |
| Net Income (ttm) | 370.49 M |
| Shares Out | 220.86 M |
| EPS (ttm) | 1.67 |
| Forward PE | 39.16 |
| Ex-Dividend Date | 12/27/2024 |
| Earnings Date | 08/08/2025 |
Celltrion's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | ₩28.62 B | -5.73% | 762 |
| 12/30/2024 | ₩40.37 T | 44.32% | 712 |
| 12/28/2023 | ₩27.97 T | 21.61% | 833 |
| 12/29/2022 | ₩23 T | -16.64% | 900 |
| 12/30/2021 | ₩27.59 T | -43.68% | 872 |
| 12/30/2020 | ₩48.99 T | 102.64% | 355 |
| 12/30/2019 | ₩24.18 T | -14.68% | 689 |
| 12/28/2018 | ₩28.33 T | 2.9% | 451 |
| 12/28/2017 | ₩27.54 T | 112.2% | 501 |
| 12/29/2016 | ₩12.98 T | 32.61% | 943 |
Company Profile
About Celltrion, Inc.
Celltrion, Inc., together with its subsidiaries, develops and produces protein-based drugs for oncology treatments in South Korea. The company operates in the biopharmaceutical sector, focusing on innovative therapies and diagnostics.
Product Offerings
- Bio Pharmaceuticals: Specialized treatments for various medical conditions.
- Generic Pharmaceuticals: Affordable alternatives to branded medications.
- COVID-19 Test Kits: Diagnostic solutions for pandemic response.
Pipeline Highlights
The company's antibody biosimilar pipeline includes several advanced-stage candidates:
- CT-P39: Phase 3 clinical trial for asthma and urticaria.
- CT-P41: Phase 3 clinical trial for osteoporosis and bone loss.
- CT-P42: Phase 3 clinical trial for diabetic macular edema.
- CT-P43: Phase 3 clinical trial for psoriasis, Crohn's disease, and ulcerative colitis.
- CT-P47: Phase 3 clinical trial for rheumatoid arthritis.
- CT-P53: Phase 3 clinical trial for multiple sclerosis.
Company Background
Founded in 2002, Celltrion, Inc. is headquartered in Incheon, South Korea, and continues to drive advancements in biopharmaceutical research and development.
Frequently Asked Questions
-
What is Celltrion's (KRX-068270) current market cap?As of 07/05/2025, Celltrion (including the parent company, if applicable) has an estimated market capitalization of $28.62 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Celltrion (KRX-068270) rank globally by market cap?Celltrion global market capitalization ranking is approximately 762 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.